Effects of Coenzyme Q10 in PSP and CBD

Phase 2

Completed

• Conditions: Neurological Disorders; Progressive Supranuclear Palsy

• Registration Number: NCT00532571
• Lead Sponsor: Lahey Clinic

Brief Summary

To compare the efficacy, safety and tolerability of Coenzyme Q 10 versus placebo in patients with atypical parkinsonian syndromes corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP) ).

Detailed Description

Not available

Study Timeline

• Study Start: 2004-01
• Study Completion: 2005-09
• Study First Submitted: 2007-09-18
• Study First Submitted QC: 2007-09-19
• Study First Posted: 2007-09-20
• Status Verified: 2018-06
• Last Update Submitted: 2018-06-14
• Last Update Posted: 2018-06-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Patients fulfilling the diagnostic criteria of PSP and CBD (above) and who were diagnosed within the past 5 years
• Age > 40
• Subjects receiving anticholinergics, amantadine, dopamine agonists, carbidopa/levodopa, eldepryl, or comtan must be on a stable dose for at least 30 days prior to baseline visit.
• Patients agreeable to participate in the study.

Exclusion Criteria

• Prior or concurrent therapy with anticholinergics, amantadine,a dopamine agonist,carbidopa/levodopa or comtan within 30 days of the baseline visit.
• Parkinsons disease or any other atypical parkinsonism; Parkinsonism due to drugs.
• History of pallidotomy, thalamotomy, deep brain stimulation or fetal tissue transplant.
• Previous use of coenzyme Q10 within 60 days of the baseline visit.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Trial Locations

Locations (1)

Lahey Clinic; 🇺🇸 Burlington, Massachusetts, United States